Access cutting-edge cerebral amyloid angiopathy treatment through this clinical trial at a research site in San Francisco. Study-provided care at no cost to qualified participants.
Access cerebral amyloid angiopathy specialists in San Francisco at no cost
This study follows strict safety protocols and ethical guidelines
All study-related cerebral amyloid angiopathy treatment provided free
The purpose of the study is to evaluate the effect of ALN-APP on measures of CAA disease progression and to characterize the safety, tolerability, and pharmacodynamics (PD) of ALN-APP in adult patients with sporadic CAA (sCAA) and Dutch-type CAA (D-CAA). The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional saf
Sponsor: Alnylam Pharmaceuticals
Check if you qualify for this cerebral amyloid angiopathy clinical trial in San Francisco, CA
If you're searching for cerebral amyloid angiopathy treatment options in San Francisco, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our San Francisco research site is actively enrolling participants for this clinical trial. You'll receive care from experienced cerebral amyloid angiopathy specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.